Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Researchers Generate Stem Cell-derived Beta-cells from Patients with Diabetes

By LabMedica International staff writers
Posted on 01 Jun 2016
Diabetes researchers have succeeded in generating functional insulin-secreting beta cells from stem cells derived from patients with the type I form of the disease.

Investigators at the Washington University School of Medicine (St. More...
Louis, MO, USA) and Harvard University (Cambridge, MA, USA) had reported previously that they had established scalable in vitro production of functional stem cell-derived beta-cells (SC-beta cells). Now, in a report published in the May 10, 2016, online edition of the journal Nature Communications, they described extending this approach to generate the first SC-beta cells from type I diabetic patients (T1D). Beta-cells are destroyed during T1D disease progression, which has made it difficult to extensively study them in the past.

The T1D SC-beta cells created in these studies where shown to express beta-cell markers, respond to glucose both in vitro and in vivo, prevent alloxan-induced diabetes in mice, and respond to anti-diabetic drugs. In addition, an in vitro disease model showed that the cells responded to different forms of beta-cell stress. Using these assays, the investigators found no major differences in T1D SC-beta cells compared with SC-beta cells derived from non-diabetic patients. Furthermore, there was no evidence of tumor development in mice that had received SC-beta cell transplants, even up to a year after the cells were implanted.

"There had been questions about whether we could make these cells from people with type I diabetes," said first author Dr. Jeffrey R. Millman, assistant professor of medicine and biomedical engineering at the Washington University School of Medicine. "Some scientists thought that because the tissue would be coming from diabetes patients, there might be defects to prevent us from helping the stem cells differentiate into beta cells. It turns out that is not the case. In theory, if we could replace the damaged cells in these individuals with new pancreatic beta cells - whose primary function is to store and release insulin to control blood glucose - patients with type I diabetes would not need insulin shots anymore. The cells we have manufactured sense the presence of glucose and secrete insulin in response. And beta cells do a much better job controlling blood sugar than diabetic patients can."

Related Links:
Washington University School of Medicine
Harvard University

Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
Gold Member
Melanoma Panel
UltraSEEK Melanoma Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.